Radioligand therapy with 177Lu-PSMA-617 of metastatic prostate cancer has already been arrived in clinical use

被引：11
|
作者：
Ahmadzadehfar, Hojjat [1 ]
Essler, Markus [1 ]
Schaefers, Michael [2 ]
Rahbar, Kambiz [2 ]
机构：
[1] Univ Hosp Bonn, Dept Nucl Med, Sigmund Freud Str 25, D-53127 Bonn, Germany
[2] Univ Hosp Muenster, Dept Nucl Med, Munster, Germany
来源：
NUCLEAR MEDICINE AND BIOLOGY | 2016年 / 43卷 / 12期
关键词：
D O I：
10.1016/j.nucmedbio.2016.08.003
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：835 / 835
页数：1
相关论文
共 50 条
  • [1] 177Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer
    von Eyben, Finn E.
    Kiljunen, Timo
    Joensuu, Timo
    Kairemo, Kalevi
    Uprimny, Christian
    Virgolini, Irene
    [J]. ONCOTARGET, 2017, 8 (39) : 66112 - 66116
  • [2] 177Lu-PSMA-617 for metastatic prostate cancer in India
    Ghose, Aruni
    Banerjee, Soirindhri
    Choudhury, Partha S.
    Maniam, Akash
    Gupta, Manoj
    Banna, Giuseppe L.
    Vasdev, Nikhil
    Ghose, Amit
    Noronha, Vanita
    Mitra, Swarupa
    [J]. LANCET REGIONAL HEALTH - SOUTHEAST ASIA, 2024, 30
  • [3] Effect of 177Lu-PSMA-617 radioligand therapy on quality of life in patients with advanced metastatic prostate cancer
    Scheer, C.
    Juptner, M.
    Zhao, Y.
    Zuhayra, M.
    Lutzen, U.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S130 - S130
  • [4] Hematotoxicity after radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617
    Zimbelmann, Stefanie
    Eppard, Elisabeth
    Hauser, Stefan
    Kuerpig, Stefan
    Yordanova, Anna
    Essler, Markus
    Ahmadzadehfar, Hojjat
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [5] Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617
    Ferdinandus, Justin
    Eppard, Elisabeth
    Gaertner, Florian C.
    Kuerpig, Stefan
    Fimmers, Rolf
    Yordanova, Anna
    Hauser, Stefan
    Feldmann, Georg
    Essler, Markus
    Ahmadzadehfar, Hojjat
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (02) : 312 - 319
  • [6] Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With 177Lu-PSMA-617
    Schlenkhoff, Carl Diedrich
    Knuepfer, Eberhard
    Essler, Markus
    Ahmadzadehfar, Hojjat
    [J]. CLINICAL NUCLEAR MEDICINE, 2016, 41 (07) : 572 - 573
  • [7] Hematotoxicity after Radioligand Therapy with 177Lu-PSMA-617 in Patients with Metastastic Prostate Cancer
    Groener, Daniel
    Baumgarten, Justus
    Davis, Karen
    Happel, Christian
    Ngoc, Christina Nguyen
    Wichert, Jennifer
    Mader, Nicolai
    Mandel, Philipp
    Nikolaos, Tselis
    Gruenwald, Frank
    Sabet, Amir
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [8] Establishing 177Lu-PSMA-617 Radioligand Therapy in a Syngeneic Model of Murine Prostate Cancer
    Fendler, Wolfgang P.
    Stuparu, Andreea D.
    Evans-Axelsson, Susan
    Luckerath, Katharina
    Wei, Liu
    Kim, Woosuk
    Poddar, Soumya
    Said, Jonathan
    Radu, Caius G.
    Eiber, Matthias
    Czernin, Johannes
    Slavik, Roger
    Herrmann, Ken
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (11) : 1786 - 1792
  • [9] Predictors of better response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617
    Ferdinandus, Justin
    Eppard, Elisabeth
    Kuerpig, Stefan
    Gaertner, Florian
    Fimmers, Rolf
    Hauser, Stefan
    Essler, Markus
    Ahmadzadehfar, Hojjat
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [10] Predictors of better response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617
    Ferdinandus, J.
    Eppard, E.
    Kuerpig, S.
    Gaertner, F.
    Fimmers, R.
    Yordanova, A.
    Hauser, S.
    Essler, M.
    Feldmann, G.
    Ahmadzadehfar, H.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S212 - S213
12345